Pharmaceuticals

Innovating to treat disease more effectively

Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2009 we received a total of 25 positive regulatory decisions in the United States, Europe and Japan.

Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.

Note that some product links are intended for US residents only.

Learn more about our Pharmaceuticals Division

A C D E F G I L M N P R S T V X Z

 

 

	Reclast/Aclasta (zoledronic acid/zoledronic acid 5 mg) Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip vertebral and non-vertebral fractures, and to increase bone mineral density Prevention of clinical fractures after hip fracture in men and women Treatment of osteoporosis in men Treatment and prevention of glucocorticoid-induced osteoporosis Prevention of postmenopausal osteoporosis Treatment of Paget’s disease of the bone
	Afinitor (everolimus) mTor inhibitor for advanced renal cell carcinoma Visit www.afinitor.com/global (non-US residents only) Visit www.afinitor.com (US residents only)